We are monitoring the impact of COVID-19 on MEA Gastroparesis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5078
Share on
Share on

MEA Gastroparesis Drugs Market Research Report – Segmented By Drug Class, Disease Type, End User and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 5078
Pages: 145

The size of the Middle East and Africa Gastroparesis Drugs market was around USD 435.96 million in 2021. It is expected to grow at a CAGR of 3.8% to reach USD 525.33 million by 2026. It captures 8% of the global market.

Gastroparesis is a medical disorder in which the natural, spontaneous movement of the stomach muscles is restricted. Gastroparesis is becoming more common, as this is a type of gastroparesis with no known cause and symptoms of vomiting, nausea, and upper abdomen pain. Dietary adjustments, antiemetic medication, prokinetics medication, and symptoms modulators can all help with these symptoms.

An increase in the incidence rate of diabetes in the population, an increase in the number of surgical procedures, and an increase in the senior population are major factors promoting the growth of the gastroparesis drugs market in MEA. In addition, ongoing gastroparesis treatments, increase in the frequency of contractions and thus enhancing gastrointestinal motility, prokinetics medications are further estimated to contribute to the growth of the gastroparesis drugs market in the MEA region. Furthermore, according to the Centers for Disease Control and Prevention, approximately 44 million people in the United States had prediabetes in 2019, resulting in a significant prevalence of gastroparesis and influencing the regional market for gastroparesis treatment.

In addition, the rising frequency of diabetic mellitus in the Middle East and Africa is another key factor boosting the market growth. Diabetes is a common cause of gastroparesis, moving the gastroparesis medicine market ahead.

It creates blood sugar and nutrition problems, impairs proper digestion, and causes vomiting. Reglan, erythromycin, antiemetics, and a range of other medications and treatments are used to treat gastroparesis, which stimulates demand for specific therapies and the entire market to some extent. However, gastroparesis drug adverse effects, a lengthy regulatory process for therapeutic approval, and difficulty diagnosing gastroparesis could stall the market. Moreover, over the forecast period, the diabetic gastroparesis treatment market is anticipated to be restrained by a lack of scientific evidence on the improvement offered by prescription pharmaceuticals and the termination of clinical trials.

This research report on the Middle East and Africa gastroparesis drugs market has been segmented and sub-segmented into the following categories:

By Drug Class:

  • Prokinetic Agents 
  • Antiemetic Agents
  • Botulinum Toxin Injections    

By Disease Class:

  • Diabetic Gastroparesis       
  • Idiopathic Gastroparesis    
  • Post-surgical Gastroparesis              
  • Others      

By End User:

  • Hospitals 
  • Pharmacies            
  • Clinics      
  • E-commerce     

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, MEA is poised for robust growth in the forecast period due to increased investments by major companies in the market. In addition, a surge in demand for user-friendly pharmaceutical development, growing healthcare infrastructure, and creative marketing initiatives by top vendors in developing countries such as the UAE and Germany are expected to present profitable market expansion opportunities throughout the projection period.

KEY MARKET PLAYERS:

Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc. Other players in the market are Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma is a few of the key players in the MEA gastroparesis drugs market.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Drug Class                  

                              5.1.1 Introduction           

                              5.1.2 Prokinetic Agents 

                              5.1.3 Antiemetic Agents

                              5.1.4 Botulinum Toxin Injections              

                              5.1.5  Y-o-Y Growth Analysis, By Drug Class          

                              5.1.6  Market Attractiveness Analysis, By Drug Class        

                              5.1.7  Market Share Analysis, By Drug Class         

               5.2 Disease Type                            

                              5.2.1 Introduction           

                              5.2.2 Diabetic Gastroparesis       

                              5.2.3 Idiopathic Gastroparesis    

                              5.2.4 Post-surgical Gastroparesis              

                              5.2.5 Others      

                              5.2.6 Y-o-Y Growth Analysis, By Disease Type      

                              5.2.7 Market Attractiveness Analysis, By Disease Type    

                              5.2.8 Market Share Analysis, By Disease Type     

               5.3 End User                     

                              5.3.1 Introduction           

                              5.3.2 Hospitals  

                              5.3.3 Pharmacies             

                              5.3.4 Clinics       

                              5.3.5 E-commerce          

                              5.3.6 Y-o-Y Growth Analysis, By End User             

                              5.3.7 Market Attractiveness Analysis, By End User            

                              5.3.8 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Drug Class

                                             6.1.3.3 By Disease Type

                                             6.1.3.4 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Drug Class

                                             6.1.4.3 By Disease Type

                                             6.1.4.4 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Drug Class

                                             6.1.5.3 By Disease Type

                                             6.1.5.4 By End User

               6.2 Middle-East                              

               6.3 Africa                          

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Allergan, Plc.                            

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Abbott Laboratories (Abbott Arzneimittel GmbH)                      

               8.3 AstraZeneca Plc.                      

               8.4 Cadila Pharmaceuticals Ltd.                

               8.5 ETX Pharma, Inc                      

               8.6 Evoke Pharma                          

               8.7 GlaxoSmithKline Plc.                             

               8.8 Neurogastrx, Inc.                    

               8.9 Valeant Pharmaceuticals International, Inc.                 

               8.10 Theravance Biopharma                      

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East and Africa Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  2. Middle East and Africa Prokinetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  3. Middle East and Africa Antiemetic Agents Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East and Africa Botulinum Toxin Injections Market, By Region, From 2021 to 2026 (USD Billion)
  5. Middle East and Africa Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  6. Middle East and Africa Diabetic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East and Africa Idiopathic Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  8. Middle East and Africa Post-surgical Gastroparesis Market, By Region, From 2021 to 2026 (USD Billion)
  9. Middle East and Africa Others Market, By Region, From 2021 to 2026 (USD Billion)
  10. Middle East and Africa Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  11. Middle East and Africa Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  12. Middle East and Africa Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)
  13. Middle East and Africa Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  14. Middle East and Africa E-commerce Market, By Region, From 2021 to 2026 (USD Billion)
  15. Middle East Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  16. Middle East Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  17. Middle East Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)
  18. Africa Gastroparesis Drugs Market, By Drug Class, From 2021 to 2026 (USD Billion)
  19. Africa Gastroparesis Drugs Market, By Disease Type, From 2021 to 2026 (USD Billion)
  20. Africa Gastroparesis Drugs Market, By End User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample